Customers & Industries
Diversify beyond EtO:
A more resilient sterilization strategy
NO₂ sterilization is increasingly recognized as a validated, sustainable alternative to legacy technologies like EtO, especially as industry demand grows for safer and more environmentally responsible and supply chain efficient methods.
Diversify your sterilant technologies for business resiliency
Is your sterilization strategy too dependent on EtO?
Ethylene oxide has long been the default sterilization pathway for many medical devices and combination products. But relying on a single modality leaves manufacturers exposed to supply, regulatory, and operational disruptions that a diversified strategy can help manage.
Why Companies Are Re-Evaluating EtO
Supply Chain Risk
EtO sterilization depends on a concentrated network of facilities and providers, creating potential business-continuity exposure when qualified alternatives are limited.
- Facility outages, capacity constraints, or provider disruptions can affect product availability, launch timing, and service costs.
- Capacity bottlenecks can increase scheduling dependency and reduce flexibility when demand or supply conditions change.
Regulatory & Litigation Pressure
EtO operations face increasing regulatory attention related to emissions and occupational exposure, adding uncertainty to the long-term operating environment.
- More stringent emissions requirements
- Greater compliance and reporting requirements
- Greater management attention to contingency planning and the availability of qualified alternatives
Operational Constraints
EtO processing can extend product lead times due to third-party scheduling constraints and aeration requirements.
- Extended sterilization and aeration timelines
- Additional inventory buffering requirements
- Dependency on outsourced sterilization schedules
- Longer product-release timelines
Financial & Working-Capital Impact
EtO dependency can create embedded financial and working-capital impacts:
- Higher working capital requirements when release timelines are extended
- Additional logistics and outsourcing coordination costs
- Production-planning uncertainty when sterilizer capacity is constrained
- Additional inventory held to protect against sterilization delays
ESG & Reputation Considerations
EtO use can bring heightened environmental, occupational, and community considerations—and greater stakeholder scrutiny.
- Community and public-health scrutiny surrounding EtO facilities
- Investor and corporate scrutiny within ESG frameworks
- Reputational exposure associated with environmental or compliance events
Beyond EtO: Building a diversified sterilization strategy
There is no single universal replacement for EtO. The more practical strategic model is to qualify additional, best-fit modalities where they make sense. Leading manufacturers are increasingly considering:
- Multi-modal sterilization portfolios
- Risk diversification across qualified sterilization pathways
- Structured evaluation of alternatives by product or product category
- Product-specific selection of the best-fit sterilization pathway
The goal is not to eliminate EtO overnight. It is to create optionality: qualify another pathway before a disruption, capacity constraint, or product need makes that alternative urgent. These considerations apply both to validating alternatives for existing products and assessing options with de novo development.
OLD MODEL
EtO only
NEW MODEL
EtO + other best-fit modalities
A practical path from EtO dependency to sterilization optionality
Quick Screen
Assess portfolio risk and identify products where an additional sterilization pathway could create value.
Rapid Assessment
Evaluate product fit and demonstrate compatibility and sterilization effectiveness.
Validate
Develop and validate a commercially scalable process that meets quality, supply-chain, and regulatory requirements.
Regulatory
Support the regulatory pathway and obtain required approvals for the additional sterilization approach.
Commercialize
Commercialize, migrate, or dual-source as appropriate to support ongoing supply needs.
Find out whether your product is a candidate for NO₂.
- Existing product? Start with an Expose & Return Study for a rapid assessment of NO₂ compatibility.
- Product in development? Schedule a Design Consultation with our experts to evaluate how NO₂ can fit into your product and sterilization strategy.
Alternative sterilization modality selection: Is NO2 a fit for your high-value product?
Noxilizer quickly helps manufacturers determine whether NO₂ is a fit and fully supports the pathway from initial evaluation through validation and commercial implementation. That means customers can evaluate an additional sterilization pathway without treating the decision as an all-or-nothing EtO replacement project. Our expertise includes:
Material compatibility
Feasibility
Validation
Regulatory documentation
Commercialization support
NO2 sterilization: Another qualified pathway to consider
Consider NO2 when:
PRODUCT CHARACTERISTICS
- Biologics / temperature-sensitive products
- Prefilled syringes
- Drug-device combination products
- Sensitive polymers
- Electronics
Operational & strategic drivers
- Short product shelf life
- Extended aeration constrains product flow
- EtO residual management is a concern
Need for sterilization resilience / optionality
- Supply chain / business continuity risk is high
Radiation (γ & x-ray)
Vaporized hydrogen peroxide (VHP)
When to consider NO2
| Characteristic / Need | NO2 | Gamma | VHP |
|---|---|---|---|
Biologic / drug-device combination product | ✓ Strong fit | ? Radiation sensitivity can be limiting | ? Oxidation sensitivity can be limiting |
Prefilled syringe / drug-delivery device | ✓ Strong fit | ? Product dependent | ? Product dependent |
Ultra-low processing temperature | ✓ 10–30°C | ✓ | ✓ |
Radiation-sensitive polymers / materials | ✓ | ✕ / ? | ✓ |
Oxidation-sensitive materials | ✓ Potential advantage | ? | ? |
Complex device / lumen penetration | ✓ Good potential | ✓ | ? Geometry dependent |
Cellulose-containing packaging | ✕ | ✓ | ✕ |
Rapid post-process release | ✓ No lengthy aeration | ✓ | ✓ |
No ionizing radiation exposure | ✓ | ✕ | ✓ |
Onsite sterilization potential | ✓ | ✕ Typically outsourced | ✓ |
Diversification from EtO | ✓ | ✓ | ✓ |
Noxilizer's UltraNox 2.0: A commercially scalable alternative to EtO
FOR EXISTING PRODUCTS, Noxilizer’s UltraNox™ 2.0 system provides a commercially scalable terminal sterilization platform for manufacturers evaluating an additional pathway beyond EtO. Its value is strongest where product compatibility, shorter release timelines, or greater sterilization optionality matter.
✓ PROOF & RISK MANAGEMENT
- Established sterilization science: Defined validation and regulatory pathway; commercialized since 2012
- Proven regulatory pathway: Technology used in products authorized by FDA and EMA
- Microbiological efficacy: Proven across multiple microorganisms
- Ideal for prefilled syringes: Minimal-vacuum process options can help address plunger movement and sterilant-ingress concerns in prefilled syringes
- EtO alternative: Different toxicological and residual profile and reduced environmental impact compared with EtO
- Supports environmental and sustainability commitments
✓ OPERATIONAL & SUPPLY-CHAIN VALUE
- Faster product release: Non-condensing NO₂ and 6–12 hour total processing cycles, including aeration, can shorten release timelines and reduce inventory requirements in appropriate applications.
- Immediate post-cycle handling: Sterilized product can be handled, packaged, or shipped following cycle completion, without extended aeration.
- Demonstrated global deployment: Multiple NO₂ sterilization systems are installed and operating globally, including in Europe and Asia
FOR NEW PRODUCTS, NO₂ sterilization’s specific features and trade-offs can provide significant benefits and may, in some cases, expand product and packaging design freedom. Noxilizer’s ultra low-temperature NO₂ sterilization platform gives development teams another terminal sterilization option — potentially expanding the materials, components and product architectures they can consider. For new products, NO₂ sterilization supports:
✓ Greater design freedom
✓ Material flexibility
✓ Complex product architectures
✓ Sustainability
Fewer trade-offs and constraints versus some alternate modalities
In summary, NO2 sterilization is an option to consider for both validating a second modality in addition to EtO, and for de novo product development.
Existing EtO product
KEY ISSUE: RISK & CONTINUITY
NO₂ sterilization benefits:
- Option to reduce EtO dependence
- Rapid path to validation
New / De novo product
KEY ISSUE: POTENTIAL PRODUCT DESIGN CONSTRAINTS
NO2 sterilization benefits:
- Fewer trade-offs
- Increased design freedom
EtO vs. NO2 sterilization: Where NO2 may offer an advantage
| Decision factor | EtO | NO2 | Why it matters |
|---|---|---|---|
Sterility Assurance Level | 0 SAL 1⁻⁶ | 0 SAL 1⁻⁶ | Both achieve the industry-standard sterility assurance level |
Processing temperature | Low (ambient–low) | Low (ambient, 10–30°C) | Enables use with heat-sensitive materials and components |
Residual concerns | tO / ECH residual limits | No EtO/ECH residuals | Avoids EtO- and ethylene chlorohydrin-related residual testing burden |
Aeration time | Extended (days) | Minimal / rapid | Faster time to release and reduced inventory holding |
Regulatory pathway maturity | Long-established, widely validated | Established, growing adoption | EtO has the longest regulatory track record; NO2 pathway is maturing |
Supply chain / geopolitical exposure | EtO supply and regulatory pressure | Independent of EtO supply constraints | Diversification reduces single-source dependency risk |
Environmental / community scrutiny | Elevated — emissions and community concerns | Lower emissions profile | Reduces regulatory and community relations exposure |
Material compatibility | Broad, well-characterized | Broad, including sensitive materials | Both support a wide range of polymers and components |
Facility footprint | Requires specialized EtO infrastructure | Compatible with on-site or contract processing | Flexibility in sterilization location and capacity planning |
Best fit | High-volume, established EtO-validated products | Diversification, sensitive or complex devices | Supports a two-pathway strategy rather than single-modality reliance |
Still have questions?
Our team can provide you with more information.
Keep exploring
Services
